Evaluation of cyclosporin‐phenytoin interaction with observations on cyclosporin metabolites.
Open Access
- 1 December 1984
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 18 (6), 887-893
- https://doi.org/10.1111/j.1365-2125.1984.tb02560.x
Abstract
We have observed that patients on concurrent cyclosporin and phenytoin therapy required increased doses of cyclosporin to maintain therapeutic concentrations of this novel immunosuppressive drug. We have, therefore, studied the influence of phenytoin on the pharmacokinetics of oral cyclosporin in six healthy male subjects. Cyclosporin concentrations in serum and whole blood were measured by high pressure liquid chromatography (h.p.l.c.) and radioimmunoassay (RIA). Concentrations of cyclosporin in whole blood were consistently higher than corresponding values in serum. Concentrations of cyclosporin determined by RIA were also consistently higher than those determined by h.p.l.c. Irrespective of the biological fluid (serum or whole blood) or the type of drug analysis (h.p.l.c. or RIA), changes in cyclosporin kinetics following phenytoin administration exhibited similar patterns. Phenytoin significantly reduced the maximum concentration and the area under the concentration‐time curve and significantly increased total body clearance of cyclosporin. There was a statistically significant reduction of cyclosporin half‐life (t 1/2) in whole blood using h.p.l.c. analysis. However, there was no significant change in cyclosporin t 1/2 in serum following phenytoin administration, using either form of drug analysis. Cyclosporin metabolites 17 and 18 were measured by h.p.l.c. in whole blood samples only, since these metabolites were found almost entirely in red blood cells. Phenytoin significantly reduced the Cmax and AUC of both metabolites, but no significant change was observed in the t 1/2 of either. Phenytoin enhanced the metabolism of antipyrine which was co‐administered with cyclosporin to assess oxidative enzyme activity. We conclude that patients undergoing organ transplantation should be carefully monitored if they require phenytoin or other drugs known to accelerate oxidative metabolism.This publication has 24 references indexed in Scilit:
- RAPID METABOLISM OF CYCLOSPORIN AND PREDNISONE IN KIDNEY TRANSPLANT PATIENT RECEIVING TUBERCULOSTATIC TREATMENTThe Lancet, 1983
- Monitoring of Cyclosporin ATherapeutic Drug Monitoring, 1983
- Abuse of Cimetidine in Outpatient PracticeNew England Journal of Medicine, 1983
- Liver Transplantation with Use of Cyclosporin a and PrednisoneNew England Journal of Medicine, 1981
- IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN AThe Lancet, 1981
- A Radioimmunoassay to Measure Cyclosporin a in Plasma and Serum SamplesJournal of Immunoassay, 1981
- High-performance liquid chromatographic determination of cyclosporin A in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979
- Enzyme InductionNew England Journal of Medicine, 1976